Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
report tags : Positive save search
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 2.19%
H: 6.15%
C: 5.35%
metabolic positive for meeting hypertension therapeutics study
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
PTPI | $0.6849 -1.86% -1.9% 150K
|
| Email alert
Add to watchlist
positive pharmaceuticals results study
C-Bond Systems Reports 2023 Highlights Including Record Revenue and Positive Net Income; Company to Host Conference Call on April 3rd
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
CBNT | News | $0.0042 122.22% 950K
|
Manufacturing
|
| O: -11.63%
H: 7.89%
C: 7.89%
conference company revenue positive
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 7.63%
H: 3.33%
C: -4.51%
year positive financial results
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Published: 2024-03-26 (Crawled : 11:00) - globenewswire.com
PRAX | $46.88 0.62% 0.62% 350K
|
Health Technology
|
| O: 19.9%
H: 11.0%
C: 2.69%
prax-628 precision positive photo response results study
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Published: 2024-03-19 (Crawled : 12:30) - prnewswire.com
ICCM | $1.23 -4.03% 120K
|
Manufacturing
|
| O: 2.07%
H: 0.0%
C: 0.0%
free company breast one positive cancer women topline medical alternative results
High Tide Reports First Quarter 2024 Financial Results Featuring Record Revenue, Record Adjusted EBITDA, and Third Consecutive Quarter of Positive Free Cash Flow as well as Break-Even Net Income
Published: 2024-03-15 (Crawled : 20:00) - hightideinc.com
HITI | $2.255 2.04% 2.0% 730K
|
Manufacturing
| Email alert
Add to watchlist
first free positive flow financial results
Alibaba Releases Report on Cross-Border Trade's Positive Impact on the U.S. Economy
Published: 2024-03-06 (Crawled : 11:00) - prnewswire.com
BABA | $69.07 0.28% -0.07% 13M
|
Retail Trade
|
| O: 2.96%
H: 0.7%
C: -0.66%
report positive impact
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
CASI | $2.24 -1.36% 10K
|
Health Technology
|
| O: 21.93%
H: 10.65%
C: -8.71%
bi-1206 report positive treatment pharmaceuticals china
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Published: 2024-02-21 (Crawled : 13:30) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -3.65%
H: 0.0%
C: -5.3%
als positive trial results
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
LRMR | $6.53 2.35% 2.3% 510K
|
Health Technology
|
| O: -16.24%
H: 26.92%
C: 20.46%
positive therapeutics study
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 2.77%
H: 2.69%
C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.41%
H: 5.51%
C: 3.26%
pharma positive trial results study
Sysco Reports Second Quarter EPS Growth, Driven By Increasing Volumes and Positive Operating Leverage
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
|
| O: 0.51%
H: 7.17%
C: 6.98%
positive
Nuclear Fuels Reports Positive Drill Results from the Kaycee Uranium Project, Wyoming
Published: 2024-01-30 (Crawled : 12:00) - prnewswire.com
EU | $4.37 -3.53% -3.66% 1.5M
|
n/a
|
| O: 0.0%
H: 5.56%
C: 4.67%
nuclear positive uranium results
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Published: 2024-01-30 (Crawled : 12:00) - globenewswire.com
KURA | $17.55 -0.74% -0.74% 1.3M
|
Health Technology
|
| O: -0.54%
H: 23.89%
C: 12.7%
positive leukemia
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.